Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

52.59 +0.96 (+1.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years
One of the best ways to spot winning stocks to buy is by spotting hot trends, such as artificial intelligence and obesity. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Viking Therapeutics Unusual Options Activity For June 12
Via Benzinga
3 Stocks Quietly Preparing for a 10X Surge: June Edition
There are plenty of 10x stocks with the potential to surge 10x over. We’ve already seen in happen with Apple, Netflix, Microsoft and Nvidia. 
Via InvestorPlace
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
The company is focusing on obesity treatment after its glaucoma drug failed. 
Via Investor's Business Daily
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Success isn't guaranteed, but both companies could become big winners. 
Via The Motley Fool
Looking At Viking Therapeutics's Recent Unusual Options Activity
Via Benzinga
What's Going On With Viking Therapeutics Stock On Tuesday?
Viking Therapeutics reports promising 52-week data from its Phase 2b VOYAGE study on VK2809 for NASH. 
Via Benzinga
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
Via Benzinga
This High-Flying Stock Just Announced More Good News: Time to Buy?
The biotech's prospects keep getting brighter. 
Via The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review
The Nasdaq and S&P 500 hit record highs, but small caps retreated. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Market Whales and Their Recent Bets on VKTX Options
Via Benzinga
Where Will Viking Therapeutics Be in 5 Years?
Could Viking Therapeutics become a big player in the GLP-1 drug market? 
Via The Motley Fool
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
Exposures Economy
Is Viking Therapeutics Stock a Buy on the Dip?
Short-term thinking is creating an intriguing opportunity for investors. 
Via The Motley Fool
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Both of these companies could soon set the standard in their fields. 
Via The Motley Fool
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
There's probably a big enough pie here for everyone to get a slice. 
Via The Motley Fool
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider. 
Via InvestorPlace
3 Underappreciated Stocks with Triple-Digit Upside: May 2024
There are plenty of underappreciated stocks on the market. In fact, here are three you may want to consider buying and holding today. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy. 
Via InvestorPlace
Exposures Product Safety
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today
What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised. 
Via The Motley Fool
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
Investors should take a close look at these biotech stocks as they position themselves to provide high returns. 
Via InvestorPlace
2 Stocks That Could 10x by 2035
These stocks are very promising, but it's important to consider the downside, too. 
Via The Motley Fool
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
Discover three top Nasdaq stocks to buy. Learn about these investment opportunities and why they’re worth your attention. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.